Pretreatment with standard-dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (ITP).

@article{Essilini2018PretreatmentWS,
  title={Pretreatment with standard-dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (ITP).},
  author={Ana{\"i}s Essilini and Thibault Comont and Johanne Germain and Natacha Brun and Claire Dingremont and Brice Castel and Sophie Arista and Serge Madaule and Laurent Sailler and Maryse Lapeyre-Mestre and Odile Beyne-Rauzy and Bertrand Godeau and Daniel Adoue and Guillaume Moulis},
  journal={European journal of haematology},
  year={2018},
  volume={100 5},
  pages={
          412-418
        }
}
OBJECTIVE To assess the benefits and harms to initiate corticosteroids with intravenous methylprednisolone at a conventional dose (1 mg/kg/d) to treat adults with immune thrombocytopenia (ITP). METHODS Population stemmed from the prospective multicenter CARMEN registry and included newly diagnosed hospitalized ITP adults with platelet counts<30 × 109 /L. We compared the patients treated with conventional-dose methylprednisolone (CDMP) before continuing with oral prednisone to patients treated… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Immune thrombocytopenia management guidelines

O Alpdogan, T Budak-Alpdogan, S Ratip
  • 2017